ChromaDex (NASDAQ:CDXC) Lowered to “Buy” Rating by StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Other research analysts also recently issued research reports about the company. Roth Mkm boosted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. HC Wainwright lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

ChromaDex Trading Up 0.5 %

Shares of NASDAQ CDXC opened at $5.51 on Friday. The business has a 50-day moving average of $6.29 and a 200-day moving average of $4.24. The firm has a market capitalization of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.21. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same period last year, the firm posted ($0.01) EPS. On average, analysts predict that ChromaDex will post 0.04 earnings per share for the current year.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BSW Wealth Partners purchased a new position in ChromaDex during the 3rd quarter valued at approximately $324,000. WINTON GROUP Ltd bought a new position in shares of ChromaDex during the 2nd quarter valued at approximately $597,000. FMR LLC purchased a new position in shares of ChromaDex in the third quarter valued at $55,000. The Manufacturers Life Insurance Company increased its position in ChromaDex by 75.4% in the third quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock worth $72,000 after purchasing an additional 8,485 shares during the last quarter. Finally, State Street Corp increased its position in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after purchasing an additional 62,692 shares during the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.